Magnetic Group Signaling (MGS®) Technology

Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.

Learn more

One Sample -

All Answers

Advanced. Automated. Affordable. Mastering Metabolite Networks for Real-Time Precision Medicine.

Learn more

AXINON® System

AXINON® is the first modular software-based system providing hardware, operating system, MGS® processor and individual test applications.

Learn more

numares AG and Oxford University to collaborate on development of Multiple Sclerosis diagnostic test

Oxford University scientists have published research on metabolomic analysis of multiple sclerosis patients (MS) by evaluating NMR spectra

numares will deploy its Magnetic Group Signaling® (MGS®) technology platform to accelerate research and development of a non-invasive MS diagnostic test

 

Regensburg, Germany, and Oxford, UK, 23 March 2017 - Fast-growing innovative diagnostics company numares AG and Oxford University are collaborating to develop an in-vitro diagnostic (IVD) test to improve therapeutic decision making for patients with multiple sclerosis (MS). The foundation for test development is based on published research conducted at Oxford to identify metabolites of MS patients by evaluating nuclear magnetic resonance spectra. numares will provide its Magnetic Group Signaling® (MGS®) technology at Oxford to enable researchers to rapidly advance their research toward the creation of a non-invasive diagnostic test.

Oxford University published the first scientific evidence for a potential diagnostic based on metabolomic analysis of MS patient samples by using nuclear magnetic resonance (NMR) technology1 , and has long-standing expertise in MS research. The disease’s transitions “relapsing remitting multiple sclerosis (RRMS)” and “secondary progressive multiple sclerosis (SPMS)” can currently only be diagnosed retrospectively. A diagnostic test that reliably identifies the emerging transition from RRMS to SPMS by detecting their different biomarker networks would improve the therapy concepts of MS patients.

Oxford is collaborating with numares to exploit the diagnostics potential of this NMR approach and transform it into a commercially available IVD product. The German company has developed its NMR-based AXINON® IVD system that evaluates NMR spectra to diagnose disease by employing the company’s proprietary MGS technology to ensure standardisation and comparability of the spectra across patient samples and NMR systems.  These basic prerequisites of the system provide the basis for collaborations between research institutions and industry to successfully apply metabolomics to human diagnostics.

Under the terms of the collaboration brokered by the institution’s research commercialisation company Oxford University Innovation, Oxford will provide samples from patients with MS and process the samples on an NMR system equipped with numares’ MGS that will be located on site at Oxford. numares has made an initial payment of an undisclosed sum and will continue to support the joint effort with additional financial contributions. If a diagnostics test is successfully developed and commercialised by numares, Oxford University will receive royalties on sales.

Professor Daniel Anthony, Head of Experimental Neuropathology Laboratory, Department of Pharmacology at the University of Oxford and lead scientist on the project, said:

“This collaboration benefits our laboratory and Oxford in several ways. First, the MGS-based AXINON®  IVD system will enable us to accelerate our research due to numares’ software-based profiling system. Second, results of the research may be directly applicable for the development of an MS IVD that could identify patients with progressing disease and help to adopt an appropriate treatment plan. Third, the university will be able to bring its application-oriented research to the patient thanks to numares’ technical and financial assistance and to participate in future royalties from a commercialised test. We are looking forward to a very productive collaboration with numares.”

Volker Pfahlert, Chief Executive Officer of numares, added: 

“Our mission is to improve patient care by providing better diagnostic tools to help physicians better manage their patients. A central part of our effort is to collaborate with researchers at academic centres to deploy our system to assist them in their work to both understand human disease and to further expand our product pipeline by developing diagnostics based on that preliminary scientific work. We are truly proud and honoured that Oxford provided us the opportunity to collaborate on this research. We are looking forward to the results of this work.”


Dickens, A., et al., A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurol., 2014.83:1492-1499.

For further information please contact:


numares AG
Dipl.-Biol. Christiane Proll, MBA
Tel.:    +49 941 2809 49-14
E-Mail: christiane.proll(at)numares.com

IRA WÜLFING KOMMUNIKATION GmbH
Dr. Reinhard Saller
Tel.:    +49 89 2000 30-30
E-Mail: reinhard.saller(at)wuelfing-kommunikation.de

U.S.A.
The Ruth Group
Investors:
Robert Flamm, Ph.D.
Tel.: 1-646-536-7017
E-Mail: rflamm(at)theruthgroup.com 

Media: 
Kirsten Thomas
Tel: 1-508-280-6592
E-Mail: kthomas(at)theruthgroup.com